Immunogenicity of pembrolizumab in patients with advanced tumors-Reference-Cited by-同舟云学术

Immunogenicity of pembrolizumab in patients with advanced tumors

Published:2019-08-08 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

van Vugt Marianne J. H.,Stone Julie A.,De Greef “Rik” H. J. M. M.,Snyder Ellen S.,Lipka Leslie,Turner David C.,Chain Anne,Lala Mallika,Li Mengyao,Robey Seth H.,Kondic Anna G.,De Alwis Dinesh,Mayawala Kapil,Jain Lokesh,Freshwater Tomoko

Funder

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0663-4.pdf

Reference21 articles.

1. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–7.

2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

3. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662–73.

4. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today. 2015;51(1):7–20.

5. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–93.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma;Frontiers in Immunology;2024-08-09

2. Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates;The AAPS Journal;2024-07-15

3. A humanized Anti-YKL-40 antibody inhibits tumor development;Biochemical Pharmacology;2024-07

4. Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review;Clinical and Translational Oncology;2024-04-24

5. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges;Frontiers in Immunology;2024-04-10